P234 Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers
Catherine Milch(Millennium Engineering and Integration (United States)), Irving H. Fox(Takeda (United States)), Jie Xu, Whitney Kent(Takeda (United States)), J Berger(University of Kentucky), T. Wyant
Cited by 7
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694